T-DXd outperformed physician’s choice of chemotherapy regardless of patients’ disease burden or time to progression on prior therapy.
Adding pembrolizumab to THP improved pCR rates in patients with HER2-positive breast cancer in the phase 2 NeoHIP trial.
Paclitaxel-based and nab-paclitaxel-based chemotherapy produced similar 5-year outcomes in patients with high-risk, HR+, HER2- early breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback